# Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease

> **NCT07547930** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 8 (estimated)

## Conditions studied

- Thyroid Eye Disease, TED
- Graves Ophthalmopathy
- Graves Orbitopathy

## Interventions

- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT07547930
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-24
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07547930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07547930, "Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07547930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*